Leading the Revolution in Treating Genetic Lung Diseases

Spirovant is focused on changing the course of cystic fibrosis and other pulmonary diseases. Our gene therapy technologies are designed to overcome the historical barriers that have prevented effective genetic treatments for cystic fibrosis.

Spirovant is the leader in the development of gene therapies for treating and curing cystic fibrosis and other lung diseases. Headquartered in Philadelphia, the company is part of a strategic alliance between Roivant Sciences and Sumitomo Dainippon Pharma. Spirovant is a nimble and driven biotech company with access to unparalleled resources to develop therapies for over 70,000 patients, 10% of whom have absolutely no existing treatments. 

Every member of Spirovant’s team is, first and foremost, deeply passionate – both about the transformative industry-leading technology and the patients who await better therapies. The company has an “all hands on deck” approach that fosters a dynamic, collaborative, and positive environment.

We’ve found that the best way to be successful is putting our employees front and center – prioritizing professional development while having fun together along the way.